Provided by Tiger Fintech (Singapore) Pte. Ltd.

X4 Pharmaceuticals Inc

4.30
+0.600016.22%
Post-market: 4.300.00000.00%19:45 EDT
Volume:265.23K
Turnover:1.12M
Market Cap:24.89M
PE:1.99
High:4.35
Open:3.83
Low:3.83
Close:3.70
Loading ...

BRIEF-X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
04 Feb

X4 said to see takeover approach from Italy’s Cheisi, Street Insider reports

TIPRANKS
·
30 Jan

X4 Pharmaceuticals Says Marketing Application for Mavorixafor Validated for Review by EU Regulator

MT Newswires Live
·
24 Jan

BRIEF-X4 Pharmaceuticals Announces EMA Validation Of Marketing Authorization Application

Reuters
·
24 Jan

X4 Pharmaceuticals Inc - Decision on Mavorixafor Maa Expected in 1H 2026

THOMSON REUTERS
·
24 Jan

X4 Pharmaceuticals Announces Ema Validation of Marketing Authorization Application (Maa) for Mavorixafor for the Treatment of Whim Syndrome

THOMSON REUTERS
·
24 Jan

January 2025's Top US Penny Stocks To Consider

Simply Wall St.
·
22 Jan

Cantor Fitzgerald Sticks to Its Buy Rating for X4 Pharmaceuticals (XFOR)

TIPRANKS
·
16 Jan

XFOR: Receives €28.5 Upfront for Licensing Agreement with Norgine…

Zacks Small Cap Research
·
15 Jan

X4 Pharmaceuticals Price Target Maintained With a $1.50/Share by HC Wainwright & Co.

Dow Jones
·
14 Jan

Analysts Have Conflicting Sentiments on These Healthcare Companies: Travere Therapeutics (TVTX), Treace Medical Concepts (TMCI) and X4 Pharmaceuticals (XFOR)

TIPRANKS
·
14 Jan

Stifel Nicolaus Remains a Buy on X4 Pharmaceuticals (XFOR)

TIPRANKS
·
14 Jan

X4 Pharmaceuticals Partners With Norgine to Commercialize Immunotherapy in Europe, Other Regions

MT Newswires Live
·
13 Jan

BRIEF-X4 Pharmaceuticals And Norgine Enter Into Exclusive Licensing Agreement To Commercialize Mavorixafor In Europe, Australia, And New Zealand

Reuters
·
13 Jan

X4 Pharmaceuticals and Norgine Enter Into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

THOMSON REUTERS
·
13 Jan

X4 Pharmaceuticals Inc - to Submit Maa to Ema for Mavorixafor in Whim Syndrome

THOMSON REUTERS
·
13 Jan

X4 Pharmaceuticals Inc - to Receive €28.5 Mln Upfront, up to €226 Mln in Milestones

THOMSON REUTERS
·
13 Jan

Grace Therapeutics And 2 Other US Penny Stocks Worth Watching

Simply Wall St.
·
21 Dec 2024